MedPath

The Role of Incretins in Bone Remodeling in Humans

Terminated
Conditions
Incretins
Osteoporosis
Healthy
Bone Remodeling
Registration Number
NCT03966261
Lead Sponsor
University Hospital, Angers
Brief Summary

The role of incretins (GIP and GLP-1) on cells and bone tissue has been shown in cellular and animal studies. In humans, the role of these hormones is mainly studied in the pathophysiology of diabetes, their effect on bone is unknown. The serum incretin concentration is low and increases rapidly after a meal. This increase is brief, incretins being rapidly degraded by dipeptidylpeptidase 4 (DPP-4). The dosage of these hormones is complex and the basal "normal" serum concentrations and after feeding in healthy subjects are unknown. Before any study on the effect of incretins on bone remodeling in humans, it is necessary to establish physiological concentrations of incretins in healthy subjects.

The aim of this study is to estimate physiological concentrations of incretins in healthy subject.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
104
Inclusion Criteria
  • healthy women and men
Exclusion Criteria
  • known osteoporosis
  • osteoporotic fracture
  • tobacco
  • alcohol : > 2 glasses/day
  • type 1 and type 2 diabetes
  • BMI < 19kg/m² or > 30kg/m²
  • heart failure, kidney failure
  • cancer
  • bariatric surgery
  • graft
  • cirrhosis
  • use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV glucocorticoid during 3 months or more

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
incretins concentrations before and after a meal in healthy subjects2 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Angers

🇫🇷

Angers, France

© Copyright 2025. All Rights Reserved by MedPath